Min HK, Kim HR, Lee SH, et al. - This study was carried out to compare drug retention and clinical efficacy between ankylosing spondylitis (AS) patients who switched biologics to secukinumab and those who switched to a different tumor necrosis factor inhibitor (TNFi). Researchers included AS patients enrolled in the Korean College of Rheumatology BIOlogics registry, and patients with non-radiographic axial spondyloarthritis were excluded. They conducted propensity score-matched and covariate-adjusted logistic regression analyses. In this study, 246 had available 1-year follow-up data. The data exhibited that switching biologics to secukinumab and switching to an alternative TNFi resulted in comparable drug retention and clinical efficacy in AS patients with previous exposure to a TNFi.